PMID- 36744150 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230207 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 10 DP - 2023 TI - Ten-year follow-up of infliximab treatment for uveitis in Behcet disease patients: A multicenter retrospective study. PG - 1095423 LID - 10.3389/fmed.2023.1095423 [doi] LID - 1095423 AB - PURPOSE: To evaluate 10-year outcome of infliximab (IFX) treatment for uveitis in Behcet disease (BD) patients using a standardized follow-up protocol. DESIGN: Retrospective longitudinal cohort study. PARTICIPANTS: 140 BD uveitis patients treated with IFX enrolled in our previous study. METHODS: Medical records were reviewed for demographic information, duration of IFX treatment, number of ocular attacks before IFX initiation, best corrected visual acuity (VA) at baseline and 1, 2, 3, 4, 5, and 10 years after IFX initiation, uveitis recurrence after IFX initiation and main anatomical site, concomitant therapies, and adverse events (AEs). MAIN OUTCOME MEASURES: 10-year IFX continuation rate and change in LogMAR VA. RESULTS: Of 140 BD patients, 106 (75.7%) continued IFX treatment for 10 years. LogMAR VA improved gradually after initiation of IFX, and the improvement reached statistical significance from 2 years of treatment. Thereafter, significant improvement compared with baseline was maintained until 10 years, despite a slight deterioration of logMAR VA from 5 years. However, eyes with worse baseline decimal VA < 0.1 showed no significant improvement from baseline to 10 years. Uveitis recurred after IFX initiation in 50 patients (recurrence group) and did not recur in 56 (non-recurrence group). Ocular attacks/year before IFX initiation was significantly higher in the recurrence group (2.82 +/- 3.81) than in the non-recurrence group (1.84 +/- 1.78). In the recurrence group, uveitis recurred within 1 year in 58% and within 2 years in 74%. Seventeen patients (34%) had recurrent anterior uveitis, 17 (34%) had posterior uveitis, and 16 (32%) had panuveitis, with no significant difference in VA outcome. In addition, logMAR VA at 10 years did not differ between the recurrence and non-recurrence groups. AEs occurred among 43 patients (30.7%), and 24 (17.1%) resulted in IFX discontinuation before 10 years. CONCLUSIONS: Among BD patients with uveitis who initiated IFX, approximately 75% continued treatment for 10 years, and their VA improved significantly and was maintained for 10 years. Uveitis recurred in one-half of the patients, but visual acuity did not differ significantly from the patients without recurrence. CI - Copyright (c) 2023 Takeuchi, Usui, Namba, Keino, Takeuchi, Takase, Kamoi, Hase, Ito, Nakai, Maruyama, Kobayashi, Mashimo, Sato, Ohguro, Hori, Okada, Sonoda, Mizuki and Goto. FAU - Takeuchi, Masaru AU - Takeuchi M AD - Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan. FAU - Usui, Yoshihiko AU - Usui Y AD - Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan. FAU - Namba, Kenichi AU - Namba K AD - Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Keino, Hiroshi AU - Keino H AD - Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan. FAU - Takeuchi, Masaki AU - Takeuchi M AD - Department of Ophthalmology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Takase, Hiroshi AU - Takase H AD - Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Kamoi, Koju AU - Kamoi K AD - Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Hase, Keitaro AU - Hase K AD - Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Ito, Takako AU - Ito T AD - Department of Ophthalmology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan. FAU - Nakai, Kei AU - Nakai K AD - Department of Ophthalmology, Yodogawa Christian Hospital, Osaka, Japan. FAU - Maruyama, Kazuichi AU - Maruyama K AD - Department of Vision Informatics, Graduate School of Medicine, Osaka University, Suita, Japan. FAU - Kobayashi, Eri AU - Kobayashi E AD - Department of Ophthalmology, Nippon Medical School, Tokyo, Japan. FAU - Mashimo, Hisashi AU - Mashimo H AD - Department of Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan. FAU - Sato, Tomohito AU - Sato T AD - Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan. FAU - Ohguro, Nobuyuki AU - Ohguro N AD - Department of Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan. FAU - Hori, Junko AU - Hori J AD - Department of Ophthalmology, Nippon Medical School, Tokyo, Japan. FAU - Okada, Annabelle A AU - Okada AA AD - Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan. FAU - Sonoda, Koh-Hei AU - Sonoda KH AD - Department of Ophthalmology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan. FAU - Mizuki, Nobuhisa AU - Mizuki N AD - Department of Ophthalmology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Goto, Hiroshi AU - Goto H AD - Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20230120 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC9894869 OTO - NOTNLM OT - Behcet disease OT - Behcet uveitis OT - biologics OT - endogenous uveitis OT - infliximab OT - non-infectious uveitis OT - uveitis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/07 06:00 MHDA- 2023/02/07 06:01 PMCR- 2023/01/20 CRDT- 2023/02/06 04:06 PHST- 2022/11/11 00:00 [received] PHST- 2023/01/05 00:00 [accepted] PHST- 2023/02/06 04:06 [entrez] PHST- 2023/02/07 06:00 [pubmed] PHST- 2023/02/07 06:01 [medline] PHST- 2023/01/20 00:00 [pmc-release] AID - 10.3389/fmed.2023.1095423 [doi] PST - epublish SO - Front Med (Lausanne). 2023 Jan 20;10:1095423. doi: 10.3389/fmed.2023.1095423. eCollection 2023.